t
Avacta Group plc announced on 2 September 2024 that on 30 August 2024, CEO Christina Coughlin was granted 3,600,000 options over ordinary shares at an exercise price of 72p. On the same date, CFO Tony Gardiner exercised 500,000 options at 10p per share and sold the resulting ordinary shares at an average price of 71.07 pence each, retaining 2,328,324 options. Following these transactions, the company's enlarged issued share capital totals 362,159,730 ordinary shares of 10p each.
| Date | 2 Sept 2024 |
| Time | 15:53:56 |
| Category | Director/PDMR dealings |
| ID | 5844C |
2 September 2024
Avacta Group plc
("Avacta", the "Group" or the "Company")
Director/PDMR Shareholdings
and
Total Voting Rights
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that a total of 3,600,000 options over ordinary shares of 10p each ("Ordinary Shares") were granted to Christina Coughlin, MD, PhD, Chief Executive Officer (the "Options") on 30 August 2024.
The Options were granted under the Company's Long Term Incentive Plan, Avacta Group plc Executive Share Option Scheme and are time-based, vesting in three equal tranches over three years to 1 May 2027. The exercise price of the Options is 72p, being the closing mid-market share price of the Company's ordinary shares on the 29 August 2024.
Also on 30 August 2024, Tony Gardiner, CFO, exercised 500,000 options and sold the resulting ordinary shares of 10p each at an average price of 71.07 pence per share. The exercise price of the options was 10p per ordinary share. Tony Gardiner continues to retain 2,328,324 options over Ordinary Shares.
As previously announced Tony Gardiner stepped down from the Board on 26 June 2024 but will be remaining as CFO until 31st October 2024 whilst the search for a new permanent CFO is undertaken.
Following the allotment of the 500,000 ordinary shares issued as a result of the exercise of options by Tony Gardiner, the Company's enlarged issued share capital is 362,159,730 ordinary shares of 10p each. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
-Ends-
For further information from Avacta Group plc, please contact:
|
Avacta Group plc Christina Coughlin, CEO Michael Vinegrad, Group Communications Director
|
Tel: +44 (0) 1904 21 7070 |
|
Peel Hunt (Nomad and Broker) James Steel / Chris Golden / Patrick Birkholm
|
|
|
ICR Consilium Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji |
|
About Avacta Group plc - www.avacta.com
Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.
Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.
Avacta Diagnostics focuses on supporting healthcare professionals and broadening access to diagnostics.
Avacta has two proprietary platforms, pre|CISION™ and Affimer®.
The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION™ platform harnesses this tumour specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.
The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Christina Coughlin |
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
Chief Executive Officer |
||||
|
b) |
Initial notification/Amendment |
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Avacta Group Plc |
||||
|
b) |
LEI |
2138009U3EG31OPMGH36 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the Financial instrument, type of instrument |
|
||||
|
Identification code |
GB00BYYW9G87 |
|||||
|
b) |
Nature of the transaction |
|
||||
|
c) |
Price(s) and volume(s) |
LTIP
|
||||
|
d) |
Aggregated information: · Aggregated volume · Price |
As above |
||||
|
e) |
Date of the transaction |
30 August 2024 |
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Tony Gardiner |
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
Chief Financial Officer |
||||
|
b) |
Initial notification/Amendment |
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Avacta Group Plc |
||||
|
b) |
LEI |
2138009U3EG31OPMGH36 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the Financial instrument, type of instrument |
|
||||
|
Identification code |
GB00BYYW9G87 |
|||||
|
b) |
Nature of the transaction |
|
||||
|
c) |
Price(s) and volume(s) |
LTIP
|
||||
|
d) |
Aggregated information: · Aggregated volume · Price |
As above |
||||
|
e) |
Date of the transaction |
30 August 2024 |
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Tony Gardiner |
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
Chief Financial Officer |
||||
|
b) |
Initial notification/Amendment |
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Avacta Group Plc |
||||
|
b) |
LEI |
2138009U3EG31OPMGH36 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the Financial instrument, type of instrument |
|
||||
|
Identification code |
GB00BYYW9G87 |
|||||
|
b) |
Nature of the transaction |
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information: · Aggregated volume · Price |
As above |
||||
|
e) |
Date of the transaction |
30 August 2024 |
||||
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market |
||||